Ambu A/S

MAJOR CLINICAL STUDY RECOMMENDS CLOSED-SYSTEM SAMPLING AS STANDARD OF CARE

17.11.2026 13:41:29 CET | Ambu A/S | Press release

Share

Using the Ambu® BronchoSampler™, researchers compared closed-system bronchoscopy sampling with conventional sampling containers and found significant safety and efficiency advantages.

Ambu A/S

Copenhagen, Denmark, 17 November 2026 – Ambu, the global market leader in single-use endoscopy, today announces the publication of results from a new multicenter randomized controlled trial (RASeCAL) that concluded closed-system bronchoscopy fluid sampling should become the standard of care in intensive care units (ICUs) and bronchoscopy suites.

The study compared Ambu’s closed-system bronchoscopy sampling solution, Ambu BronchoSampler, with conventional specimen-trap sampling methods used during bronchoalveolar lavage (BAL) and bronchial washing procedures.

Published in BMJ Open Respiratory Research by Suveer Singh et al., the study is the largest prospective bronchoscopy randomized controlled trial in the ICU setting to date, with 188 critically ill patients enrolled across eight hospitals in the United Kingdom.

The study found that closed-system bronchoscopy sampling, evaluated using Ambu’s BronchoSampler solution, is significantly safer and more efficient from a procedural perspective than conventional sampling, concluding that, “Closed-system bronchoscopic sampling was safer (less spill and unplanned disconnections) and more efficient (setup, connectivity and loss prevention) than standard containers", and that, “closed-system fluid sampling should become the standard of care in the ICU and bronchoscopy suite."*

Significant results from the randomized controlled trial using Ambu BronchoSampler (ABS) included:

  • Sample spills: 0% sample spills were observed with the ABS closed-system sampling, compared with a spill rate of 23.7% for conventional sampling containers.
  • Unplanned tube disconnections: The ABS closed-system sampling saw 75% fewer unplanned interruptions, with unplanned tube disconnections occurring in 5.3% of procedures compared with 21.5% for conventional sampling containers.
  • Connectivity: Higher connectivity ratings with the ABS closed-system sampling, with 100% of researchers rating connectivity as easy, or very easy, compared with 54.7% for conventional sampling containers.
  • Sample loss to wall suction: The ABS closed-system sampling saw a 76% reduction in loss of sample to wall suction, with sample loss to wall suction occurring in 11.6% of procedure using ABS closed-system sampling compared with 48.4% for conventional sampling containers.


The study also highlighted the relevance of closed-system sampling in situations involving high-risk airborne infections where aerosolization is a concern for healthcare professionals. Notably, the authors noted that “Practicalities of performing bronchial washes would suggest the adoption of closed systems like the ABS [Ambu BronchoSampler].”*

In 2019, Ambu was the first company to introduce a closed-system sampling solution for bronchoscopy. The Ambu BronchoSampler continues to be a one-of-a-kind system due to its closed-loop three-way valve mechanism that enables precise control of bronchial fluid flow during sampling. Today, the Company offers BronchoSampler solutions for both its aScope™ 4 Broncho and aScope™ 5 Broncho endoscope portfolios, each incorporating the three-way valve mechanism. 

Reflecting on the implications of the findings, the authors highlighted three-way valve systems as a model for future innovation, noting that, “the evidence from this multicentre study is promising and should engage sample container and bronchoscopy companies to consider and develop these systems, based on a three-way valve mechanism, for improved standards of bronchoscopic sampling.”* The authors further observed that, “whether similar closed system sampling mechanisms are developed, and how safe and effective they are, remains speculative.”*

The full RASeCAL study received financial support from Ambu A/S and is publicly available in BMJ Open Respiratory Research.


___________________________________

* Singh S., et al., Randomised controlled trial to assess the safety and efficiency of a self-contained sampling device/disposable bronchoscope system versus usual sampling procedure (RASECAL), 2026.

Keywords

Contacts

About Ambu

Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,400+ Ambu team members are committed to delivering above and beyond.

For more information, please visit Ambu.com.

Subscribe to releases from Ambu A/S

Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Ambu A/S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye